IQVIA Holdings Inc. $IQV Stake Reduced by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 41.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,923 shares of the medical research company’s stock after selling 5,717 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in IQVIA were worth $2,065,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Cyndeo Wealth Partners LLC bought a new stake in shares of IQVIA during the 3rd quarter worth $315,000. Hanson & Doremus Investment Management increased its stake in IQVIA by 1.7% in the third quarter. Hanson & Doremus Investment Management now owns 15,699 shares of the medical research company’s stock valued at $4,221,000 after acquiring an additional 257 shares during the last quarter. Pension & Wealth Management Advisors Inc. bought a new position in IQVIA in the third quarter valued at $30,000. Howard Capital Management LLC bought a new position in IQVIA in the third quarter valued at $242,000. Finally, Goelzer Investment Management Inc. raised its position in IQVIA by 2.7% during the third quarter. Goelzer Investment Management Inc. now owns 11,090 shares of the medical research company’s stock valued at $2,982,000 after purchasing an additional 290 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on IQV shares. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, September 12th. TD Cowen upped their price objective on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. William Blair upgraded IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a report on Thursday, July 9th. Finally, Stifel Nicolaus boosted their target price on IQVIA from $276.00 to $303.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $276.00.

Insider Activity at IQVIA

In related news, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 15,581 shares of company stock worth $3,796,021 over the last three months. Corporate insiders own 1.70% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $276.56 on Thursday. The company has a 50-day simple moving average of $262.40 and a two-hundred day simple moving average of $215.24. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $277.40. The firm has a market cap of $45.52 billion, a price-to-earnings ratio of 34.31, a PEG ratio of 2.35 and a beta of 1.17.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period last year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 11.55 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.